Taksta: Ph III data
Top-line data from 716 ABSSSI patients in the ITT population of a double-blind, U.S. Phase III trial showed that oral Taksta met the primary endpoint of non-inferiority to oral linezolid in early
Gathering data...
Top-line data from 716 ABSSSI patients in the ITT population of a double-blind, U.S. Phase III trial showed that oral Taksta met the primary endpoint of non-inferiority to oral linezolid in early